Serum untargeted lipidomic profiling reveals dysfunction of phospholipid metabolism in subclinical coronary artery disease

References

• Szummer K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. Eur Heart J. 2017;38(41):3056–3065. doi:10.1093/eurheartj/ehx51529020314
   PubMed Web of Science ®Google Scholar
• Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231–1243. doi:10.1016/S0140-6736(11)61215-421872920
   PubMed Web of Science ®Google Scholar
• Tunstall-Pedoe H, Vanuzzo D, Hobbs M, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet. 2000;355(9205):688–700.10703800
   PubMed Web of Science ®Google Scholar
• Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168(2):934–945. doi:10.1016/j.ijcard.2012.10.04623218570
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–753. doi:10.1161/CIRCULATIONAHA.107.69957918212285
   PubMed Web of Science ®Google Scholar
• Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73. doi:10.1161/01.cir.0000437741.48606.9824222018
   PubMed Web of Science ®Google Scholar
• Peters SA, Den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart. 2012;98(3):177–184. doi:10.1136/heartjnl-2011-30074722095617
   PubMed Web of Science ®Google Scholar
• Qamar A, Khetarpal SA, Khera AV, Qasim A, Rader DJ, Reilly MP. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol. 2015;35(8):1880–1888. doi:10.1161/ATVBAHA.115.30541526069232
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Moura L. The lipid hypothesis in calcific aortic valve disease: the role of the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36(5):774–776. doi:10.1161/ATVBAHA.116.30743527122627
   PubMed Web of Science ®Google Scholar
• Wong ND, Kouwabunpat D, Vo AN, et al. Coronary calcium and atherosclerosis by ultrafast computed tomography in asymptomatic men and women: relation to age and risk factors. Am Heart J. 1994;127(2):422–430.8296711
   PubMed Web of Science ®Google Scholar
• Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol. 1996;27(2):277–284.8557894
   PubMed Web of Science ®Google Scholar
• Paramsothy P, Katz R, Owens DS, Burke GL, Probstfield JL, O’Brien KD. Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2010;105(3):352–358. doi:10.1016/j.amjcard.2009.09.04020102947
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–458. doi:10.1161/CIRCULATIONAHA.106.63779317190864
   PubMed Web of Science ®Google Scholar
• Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–1352. doi:10.1038/ng.279524097064
   PubMed Web of Science ®Google Scholar
• Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34(24):1826–1833. doi:10.1093/eurheartj/ehs43123248205
   PubMed Web of Science ®Google Scholar
• Djekic D, Nicoll R, Novo M, Henein M. Metabolomics in atherosclerosis. IJC Metab Endocr. 2015;8:26–30. doi:10.1016/j.ijcme.2014.11.004
   Google Scholar
• Janowitz WR, Agatston AS, Viamonte M. Comparison of serial quantitative evaluation of calcified coronary artery plaque by ultrafast computed tomography in persons with and without obstructive coronary artery disease. Am J Cardiol. 1991;68(1):1–6.2058541
   PubMed Web of Science ®Google Scholar
• Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. 2010;11:395. doi:10.1186/1471-2105-11-39520650010
   PubMed Web of Science ®Google Scholar
• Bowden JA, Heckert A, Ulmer CZ, et al. Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res. 2017;58(12):2275–2288. doi:10.1194/jlr.M07901228986437
   PubMed Web of Science ®Google Scholar
• Jolliffe IT. Principal Component Analysis. 2nd ed. New York: Springer; 2002.
   Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289–300. doi:10.1111/rssb.1995.57.issue-1
   Web of Science ®Google Scholar
• Hartigan JA, Wong MA. A K-means clustering algorithm. J R Stat Soc Ser C Appl Stat. 1979;28:100–108.
   Google Scholar
• Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math. 1987;20:53–65. doi:10.1016/0377-0427(87)90125-7
   Web of Science ®Google Scholar
• Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368(19):1845–1846. doi:10.1056/NEJMc1303158
   PubMed Web of Science ®Google Scholar
• Verheye S, Martinet W, Kockx MM, et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49(6):706–715. doi:10.1016/j.jacc.2006.09.04717291937
   PubMed Web of Science ®Google Scholar
• Liao X, Sluimer JC, Wang Y, et al. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 2012;15(4):545–553. doi:10.1016/j.cmet.2012.01.02222445600
   PubMed Web of Science ®Google Scholar
• Rockenfeller P, Koska M, Pietrocola F, et al. Phosphatidylethanolamine positively regulates autophagy and longevity. Cell Death Differ. 2015;22:499. doi:10.1038/cdd.2014.21925571976
   PubMed Web of Science ®Google Scholar
• Akiba S, Yoneda Y, Ohno S, Nemoto M, Sato T. Oxidized LDL activates phospholipase A2 to supply fatty acids required for cholesterol esterification. J Lipid Res. 2003;44(9):1676–1685. doi:10.1194/jlr.M300012-JLR20012777475
   PubMed Web of Science ®Google Scholar
• Brilakis ES, Khera A, Saeed B, et al. Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. Clin Chem. 2008;54(12):1975–1981. doi:10.1373/clinchem.2008.10735918832472
   PubMed Web of Science ®Google Scholar
• Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111(5):570–575. doi:10.1161/01.CIR.0000154553.12214.CD15699277
   PubMed Web of Science ®Google Scholar
• Pokharel Y, Sun W, Polfus LM, et al. Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2015;241(2):641–648. doi:10.1016/j.atherosclerosis.2015.06.03326117401
   PubMed Web of Science ®Google Scholar
• Garg PK, McClelland RL, Jenny NS, et al. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: the multi ethnic study of atherosclerosis. Atherosclerosis. 2015;241(1):176–182. doi:10.1016/j.atherosclerosis.2015.05.00626004387
   PubMed Web of Science ®Google Scholar
• White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–1711. doi:10.1056/NEJMoa131587824678955
   PubMed Web of Science ®Google Scholar
• Vorkas PA, Isaac G, Holmgren A, et al. Perturbations in fatty acid metabolism and apoptosis are manifested in calcific coronary artery disease: an exploratory lipidomic study. Int J Cardiol. 2015;197:192–199. doi:10.1016/j.ijcard.2015.06.04826142205
   PubMed Web of Science ®Google Scholar
• Djekic D, Pinto R, Vorkas PA, Henein MY. Replication of LC-MS untargeted lipidomics results in patients with calcific coronary disease: an interlaboratory reproducibility study. Int J Cardiol. 2016;222:1042–1048. doi:10.1016/j.ijcard.2016.07.21427543723
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Wong G, Tsorotes D, et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol. 2011;31(11):2723–2732. doi:10.1161/ATVBAHA.111.23409621903946
   PubMed Web of Science ®Google Scholar
• Sutter I, Klingenberg R, Othman A, et al. Decreased phosphatidylcholine plasmalogens–a putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. Atherosclerosis. 2016;246:130–140. doi:10.1016/j.atherosclerosis.2016.01.00326773473
   PubMed Web of Science ®Google Scholar
• Sousa B, Melo T, Campos A, et al. Alteration in phospholipidome profile of myoblast H9c2 cell line in a model of myocardium starvation and ischemia. J Cell Physiol. 2016;231(10):2266–2274. doi:10.1002/jcp.2534426887290
   PubMed Web of Science ®Google Scholar
• Paapstel K, Kals J, Eha J, et al. Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis. Nutr Metab Cardiovasc Dis. 2018;28(1):44–52. doi:10.1016/j.numecd.2017.07.01128986077
   PubMed Web of Science ®Google Scholar
• Fernandez C, Sandin M, Sampaio JL, et al. Plasma lipid composition and risk of developing cardiovascular disease. PLoS One. 2013;8(8):e71846. doi:10.1371/journal.pone.007184623967253
   PubMed Web of Science ®Google Scholar
• Mahendran Y, Vangipurapu J, Cederberg H, et al. Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men. Diabetes. 2013;62(10):3618–3626. doi:10.2337/db12-136323557707
   PubMed Web of Science ®Google Scholar
• Braun JE, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J. 1992;287(Pt 2):337–347.1445192
   PubMedGoogle Scholar
• Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol. 2010;9:9. doi:10.1186/1475-2840-9-920158910
   PubMed Web of Science ®Google Scholar
• Barazzoni R, Zanetti M, Gortan Cappellari G, et al. Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-κB inhibitor (IκB)-nuclear factor-κB (NFκB) activation in rat muscle, in the absence of mitochondrial dysfunction. Diabetologia. 2012;55(3):773–782. doi:10.1007/s00125-011-2396-x22159911
   PubMed Web of Science ®Google Scholar
• Boden G, She P, Mozzoli M, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes. 2005;54(12):3458–3465.16306362
   PubMed Web of Science ®Google Scholar
• Brodeur MR, Bouvet C, Barrette M, Moreau P. Palmitic acid increases medial calcification by inducing oxidative stress. J Vasc Res. 2013;50(5):430–441. doi:10.1159/00035423524080574
   PubMed Web of Science ®Google Scholar
• Alshehry ZH, Mundra PA, Barlow CK, et al. Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. Circulation. 2016;134(21):1637–1650. doi:10.1161/CIRCULATIONAHA.116.02323327756783
   PubMed Web of Science ®Google Scholar
• Stegemann C, Pechlaner R, Willeit P, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014;129(18):1821–1831. doi:10.1161/CIRCULATIONAHA.113.00250024622385
   PubMed Web of Science ®Google Scholar
• Rhee EP, Cheng S, Larson MG, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121(4):1402–1411. doi:10.1172/JCI4444221403394
   PubMed Web of Science ®Google Scholar
• Borland SJ, Morris TG, Borland SC, et al. Regulation of vascular smooth muscle cell calcification by syndecan-4/FGF-2/PKCα signalling and cross-talk with TGFβ. Cardiovasc Res. 2017;113(13):1639–1652. doi:10.1093/cvr/cvx17829016732
   PubMed Web of Science ®Google Scholar
• Nicoll R, Wiklund U, Zhao Y, et al. Gender and age effects on risk factor-based prediction of coronary artery calcium in symptomatic patients: a Euro-CCAD study. Atherosclerosis. 2016;252:32–39. doi:10.1016/j.atherosclerosis.2016.07.90627494449
   PubMedGoogle Scholar
• Djekic D, Angerås O, Lappas G, et al. Impact of socioeconomic status on coronary artery calcification. Eur J Prev Cardiol. 2018;25(16):1756–1764. doi:10.1177/204748731879210330095278
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Wong G, Barlow CK, Kingwell BA. Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol Ther. 2014;143(1):12–23. doi:10.1016/j.pharmthera.2014.02.00124509229
   PubMed Web of Science ®Google Scholar